TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Tonix Pharmaceuticals
Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

Tonix Pharmaceuticals is collaborating with Massachusetts General Hospital to conduct a Phase 2 clinical trial of TNX-1500, a monoclonal antibody designed to prevent kidney transplant rejection with potentially reduced immunosuppressive drug side effects.

Insights
AVTR   negative

Stock experienced significant decline of 23.6% following Powell's comments


TNXP   positive

Company is advancing innovative therapeutic approach for kidney transplant rejection, collaborating with a leading research hospital, and demonstrating progress in clinical development